Ayuh Ventures
VC Fund
Ayuh Ventures is an early stage longevity fund investing in technologies focused on addressing mental health, neurological disorders, inflammatory diseases, sexual & reproductive health, and aging
- Total investments:
- 10
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Ayuh Ventures invests in
Health CareBiotechnologyTherapeuticsPharmaceuticalMedical
Stages Ayuh Ventures invests in
SeedPre-SeedSeries ASeries BConvertible Note
Countries Ayuh Ventures invests in
United StatesUnited Kingdom
Round sizes
Seed $5M–$12M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Seed
- $5M–$12M
Investment Focus
Industry
- Health Care 7 (70%)
- Biotechnology 5 (50%)
- Therapeutics 3 (30%)
- Pharmaceutical 3 (30%)
- Medical 2 (20%)
Stage
- Seed 4 (40%)
- Pre-Seed 2 (20%)
- Series A 1 (10%)
- Series B 1 (10%)
- Convertible Note 1 (10%)
Country
- United States 6 (60%)
- United Kingdom 2 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Kunal Sethi
General Partner
|
General Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Samphire Neuroscience
|
Samphire Neuroscience builds clinically validated neurotechnology to support women across their lives. Our wearable devices, Nettle™ and Lutea™, are built on the same underlying brain-stimulation technology, targeting neural pathways involved in pain, mood, stress, and sleep regulation. - Lutea™ is available globally as a wellness device. Itstimulates the same regions of the brain to support stress regulation, sleep, and recovery - key drivers of readiness and long-term performance - allowing athletes and teams to move beyond wellbeing education alone to practical, evidence-based intervention. - Nettle™ is a CE-marked (EU and UK regulated), drug- and hormone-free device that has been clinically shown to improve pain, mood, functionality, and the ability to train during the menstrual cycle, with measurable benefits after one month of use - supporting athletes to maintain training intensity and movement quality during their period. - The Samphire App is the platform controlling all Samphire hardware products with the use of CycleSync™ AI technology: the only one of its kind to support personalized neurotechnology use for women. | $5M / Seed / Jun 03, 2025 | |
|
Samphire Neuroscience
|
Samphire Neuroscience builds clinically validated neurotechnology to support women across their lives. Our wearable devices, Nettle™ and Lutea™, are built on the same underlying brain-stimulation technology, targeting neural pathways involved in pain, mood, stress, and sleep regulation. - Lutea™ is available globally as a wellness device. Itstimulates the same regions of the brain to support stress regulation, sleep, and recovery - key drivers of readiness and long-term performance - allowing athletes and teams to move beyond wellbeing education alone to practical, evidence-based intervention. - Nettle™ is a CE-marked (EU and UK regulated), drug- and hormone-free device that has been clinically shown to improve pain, mood, functionality, and the ability to train during the menstrual cycle, with measurable benefits after one month of use - supporting athletes to maintain training intensity and movement quality during their period. - The Samphire App is the platform controlling all Samphire hardware products with the use of CycleSync™ AI technology: the only one of its kind to support personalized neurotechnology use for women. | $2.3M / Pre-Seed / Feb 21, 2024 | |
|
Samphire Neuroscience
|
Samphire Neuroscience builds clinically validated neurotechnology to support women across their lives. Our wearable devices, Nettle™ and Lutea™, are built on the same underlying brain-stimulation technology, targeting neural pathways involved in pain, mood, stress, and sleep regulation. - Lutea™ is available globally as a wellness device. Itstimulates the same regions of the brain to support stress regulation, sleep, and recovery - key drivers of readiness and long-term performance - allowing athletes and teams to move beyond wellbeing education alone to practical, evidence-based intervention. - Nettle™ is a CE-marked (EU and UK regulated), drug- and hormone-free device that has been clinically shown to improve pain, mood, functionality, and the ability to train during the menstrual cycle, with measurable benefits after one month of use - supporting athletes to maintain training intensity and movement quality during their period. - The Samphire App is the platform controlling all Samphire hardware products with the use of CycleSync™ AI technology: the only one of its kind to support personalized neurotechnology use for women. | Pre-Seed / Aug 24, 2022 | |
Kanna Health
|
Kanna Health is a preclinical stage company that is developing novel therapeutics based on kanna, also known as Sceletium tortuosum. Kanna is a medicinal succulent that has been used for centuries by the San hunter-gatherers of South Africa. | $3.8M / Convertible Note / May 15, 2022 | |
Gilgamesh Pharmaceuticals
|
Gilgamesh Pharmaceuticals focuses on developing therapeutics that target neuropsychiatric and central nervous system conditions using small molecules derived from research on psychedelic compounds. The company designs and tests compounds that aim to modulate brain pathways involved in mental health disorders while reducing hallucinogenic effects.Its pipeline includes drug candidates intended for conditions such as depression, anxiety, and substance use disorders. Gilgamesh Pharmaceuticals conducts preclinical and clinical studies to evaluate the safety, dosing, and efficacy of its compounds. The company integrates medicinal chemistry, neuroscience, and clinical research to support drug development and regulatory progression. | Series B / May 01, 2022 | |
Psy Therapeutics
|
Psy Therapeutics is discovering and developing novel medicines to improve the lives of people affected by central nervous system (CNS) disorders. The company focuses on anxiety, depression, and dementia to improve neuropsychiatric care. | Seed / Apr 05, 2022 | |
Reset Pharmaceuticals
|
Reset Pharma is a biotechnology company that focuses on the development and commercialization of novel psychedelic treatments for patients with life-threatening illnesses, including cancer. Its program focuses on psilocybin with psychotherapy for patients with cancer-related demoralization, anxiety, and depression. | $11.1M / Series A / Feb 16, 2022 | |
Mindstate Design Labs
|
Mindstate Design Labs is a clinical-stage AI neuroengineering platform developing novel psychoactive drug classes for psychiatric disease indications. The company's Osmanthus ensemble of AI models maps the molecular biology of human emotional and cognitive states by integrating the world’s largest datasets of psychoactive pharmacology andsubjective experience. Mindstate's lead program MSD-001 received FDA and EMA approval for Phase I human trials in 2024.Mindstate Design Labs is a Y Combinator company backed by Initialized Capital and other top-tier investors including the founders of OpenAI, Neuralink, Coinbase, Instacart, AngelList, Twitch, and IVADO. The company was founded by biotech venture investor & serial operator Dillan DiNardo and by computer scientist & evolutionary biologist Dr. Thomas Ray, who is famous for instantiating biological phenomena in emergent machine learning systems. | $11.5M / Seed / Feb 10, 2022 | |
Clerkenwell Health
|
Clerkenwell Health is an innovative mental health company offering clinical research support services and psychedelic-assisted therapies. By providing independent psychedelic-specialist CRO services, Clerkenwell will accelerate the adoption of these treatments across Europe. The team are passionate about putting patients at the centre ofclinical trial design and delivering gold standard therapy protocols. | Pre-Seed / Feb 01, 2022 | |
Lief Therapeutics
|
Lief Therapeutics is a medical device developer whose goal is to revolutionize at-home care for post-traumatic stress disorder, depression, and anxiety. The device teaches users how to control the body's natural stress response through vibratory biofeedback exercises, allowing them to measure heart rate and breath with medical accuracy inorder to control stress. | Seed / Jul 15, 2021 |
Co-Investors
SOSV
6 deals together
Seaside Ventures
4 deals together
AfterWork Ventures
2 deals together
Empath Ventures
2 deals together
FIRSTPICK
2 deals together
SOSV HAX
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
Health Care Investors in United States
21,541 investors
FAQ
What does Ayuh Ventures invest in?
Ayuh Ventures invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Seed and Pre-Seed stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Ayuh Ventures's check size?
Ayuh Ventures typically joins rounds of $5M–$12M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Ayuh Ventures participates in.
How do I contact Ayuh Ventures?
Public channels for Ayuh Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Ayuh Ventures?
The team at Ayuh Ventures includes Kunal Sethi (General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
